MLICM
PLX icon

Metropolitan Life Insurance Company (MetLife)’s Protalix BioTherapeutics PLX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,354
Closed -$6.71K – 2436
2023
Q2 		$6.71K Buy
+3,354
New +$7.99K ﹤0.01% 2436

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PLX Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Protalix BioTherapeutics (PLX) in Q3 2023, closing a stake of 3,354 shares — an estimated $6.71K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PLX in Q2 2023 and held it in 1 quarter. The position peaked at $6.71K in Q2 2023. 61 funds tracked by Wall St. Rank hold PLX as of Q3 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Protalix BioTherapeutics position as of Q3 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,354 Protalix BioTherapeutics shares in Q3 2023, an estimated $6.71K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Protalix BioTherapeutics in Q2 2023 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Protalix BioTherapeutics position peaked at $6.71K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.